A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 441 participants.

Also called NCT01191255

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 441 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01191255
Other papers using this trial's data
  • Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data Drugs in R&D, 2015-09 DOI, PubMed 26239948, PMC4561055 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Israel, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01191255. Randomized; no masking; primary purpose prevention. Start 2010-10 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2014-12-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
Condition
Hyperphosphatemia
Condition
Kidney Failure
Intervention (Drug)
ferric citrate, ca acetate, sevelamer carbonate, placebo
Lead sponsor
Keryx Biopharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01191255
Content hash
1abd589fefece1ea62be4cd97e000a50af828f47006ddda4fb31e08fa1d5e276